AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25168034
Drug: Lozenge (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lozenge (n = 356)
Trial: 17145534
Drug: High-dose three-dimensional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose three-dimensional conformal radiotherapy (3DCRT) at 66 Gy, 2 Gy/fraction
Trial: 14505088
Drug: Penciclovir (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penciclovir (intravenous formulation)
Trial: 14505088
Drug: Topical penciclovir
RxNorm normalized name: penciclovir Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical penciclovir
Trial: 14505088
Drug: Oral famciclovir
RxNorm normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral famciclovir
Trial: 9371351
Drug: Moderate-dose trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate-dose trimethoprim (10 mg/kg/day)
Trial: 9371351
Drug: High-dose trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose trimethoprim (20 mg/kg/day)
Trial: 30616699
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate aqueous nasal spray (Nasonex) 100 mcg/day for four weeks
Trial: 16366763
Drug: Cocaine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (300 mg)
Trial: 21426558
Drug: Chiropractic spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic spinal manipulative therapy (SMT) plus home exercise program (HEP)
Trial: 14742346
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy website (MoodGYM)
Trial: 9161740
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2 g propacetamol and 50 mg ketoprofen (group 4)
Trial: 9161740
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g propacetamol (group 2)
Trial: 9161740
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ketoprofen (group 3)
Trial: 8203367
Drug: Routine blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine blood flow at 419 mL/min
Trial: 8203367
Drug: Low blood
RxNorm normalized name: Glucagon Emergency Kit for Low Blood Sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low blood flow at 200 mL/min
Trial: 8203367
Drug: Stop flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop flow technique at 419 mL/min
Trial: 8203367
Drug: Low blood
RxNorm normalized name: Glucagon Emergency Kit for Low Blood Sugar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low blood flow technique at 419 mL/min
Trial: 2955955
Drug: Oxygenated autologous
RxNorm normalized name: chondrocytes, autologous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygenated autologous blood perfusion at 60 ml/min
Trial: 12368787
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection
Trial: 27417703
Drug: Four times
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four times daily insulin (q.i.d) regimen
Trial: 27417703
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily insulin (b.i.d) regimen
Trial: 23396509
Drug: Ribavirin (1000-1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (1000-1200 mg/d) for 4 weeks
Trial: 23536652
Drug: Ribavirin monotherapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin monotherapy
Trial: 22493916
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication group (Methylcobalamin)
Trial: 19838812
Drug: Low SPGI
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low SPGI (< 25 microg/l)
Trial: 19838812
Drug: Normal SPGI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal SPGI (>= 25 microg/l)
Trial: 9202916
Drug: Droperidol 1
RxNorm normalized name: droperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1 mg
Trial: 8694168
Drug: Droperidol 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.5 mg
Trial: 1654183
Drug: Splint combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splint combined with injection
Trial: 6671816
Drug: Yoga program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga program (10 weeks, regular attendance, daily practice for white elders)
Trial: 28771671
Drug: Tailored vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored vitamin K dosing regimen (based on index INR and body surface area)
Trial: 28771671
Drug: Fixed-dose vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose vitamin K regimen (1 or 2 mg)
Trial: 28771671
Drug: Tailored vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored vitamin K dosing regimen
Trial: 28771671
Drug: Fixed-dose vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose vitamin K regimen
Trial: 26249766
Drug: Ibuprofen lysinate
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen lysinate (Algidrin® Pediátrico, FARDI S.A.)
Trial: 26249766
Drug: Ibuprofen base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen base (Dalsy®, Abbott Laboratories S.A.)
Trial: 19947259
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Ibuprofen sustained release capsule)
Trial: 19947259
Drug: Waiting group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting group (no treatment)
Trial: 17391568
Drug: cis-isomer-rich tomato
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis-isomer-rich tomato sauce (26.4 mg total lycopene/100 g sauce; 45 % cis-isomers)
Trial: 17391568
Drug: all-trans-rich tomato
RxNorm normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all-trans-rich tomato sauce (32.5 mg total lycopene/100 g sauce; 5 % cis-isomers)
Trial: 10977106
Drug: Beta-carotene (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (50 mg, alternate days)
Trial: 19509109
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic agents (OHA)
Trial: 8444822
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg daily of oral zinc sulphate for 6 weeks)
Trial: 3538262
Drug: Treatment in
RxNorm normalized name: Other agents for local oral treatment in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in one stage of the trial
Trial: 3538262
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment in adjacent stage
Trial: 11016522
Drug: Modified assertive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified assertive community treatment
Trial: 26948484
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment at community mental health centres
Trial: 25491618
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fentanyl (2 mcg/kg)
Trial: 25491618
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fentanyl (40-70 mcg/kg)
Trial: 18375321
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (SA)
Trial: 16636210
Drug: Ximelagatran, 36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran, 36 mg twice daily
Trial: 15701910
Drug: Warfarin (adjusted-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted-dose aiming for INR 2.0 to 3.0)
Trial: 18574928
Drug: Ximelagatran and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran and Warfarin
Trial: 17329296
Drug: Conventional antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotics (CA)
Trial: 10658044
Drug: Water +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water + Carbohydrate (3.39 +/- 0.23 liters of solution containing 204 +/- 14 g of carbohydrate)
Trial: 10658044
Drug: Carbohydrate (204
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (204 +/- 14 g in 0.49 +/- 0.03 liter of solution)
Trial: 1831248
Drug: Epidural infusions
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusions of sufentanil citrate
Trial: 1831248
Drug: Epidural infusions
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusions of morphine in 0.5% bupivacaine (MS-MARC)
Trial: 1831248
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from initial sufentanil citrate infusions to MS-MARC
Trial: 29098341
Drug: Roflumilast 100
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast 100 μg
Trial: 30776650
Drug: Roflumilast 250
RxNorm normalized name: ROFLUMILAST 250MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 250 μg
Trial: 30776650
Drug: Roflumilast 1000
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast 1000 μg
Trial: 22247360
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with conventional combination therapy for 24 months
Trial: 19201183
Drug: Lutein-fortified fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein-fortified fermented milk (high content, 16 mg lutein)
Trial: 19201183
Drug: Lutein-fortified fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein-fortified fermented milk (low content, 8 mg lutein)
Trial: 16326293
Drug: Magnesium sulfate,
RxNorm normalized name: MAGNESIUM SULFATE,ANHYDROUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulfate, 2 g/70 kg, infused intravenously during and for 3 days postoperatively
Trial: 16326293
Drug: Codeine, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine, 60 mg/70 kg, given orally 4 times a day for 3 days
Trial: 16326293
Drug: Diclofenac sodium,
RxNorm normalized name: diclofenac sodium, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac sodium, 75 mg, given orally twice a day for 3 days
Trial: 9617980
Drug: Venlafaxine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (37.5 mg twice a day)
Trial: 9617980
Drug: Venlafaxine (37.5-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (37.5-75 mg twice a day)
Trial: 9617980
Drug: Mianserin (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (10-20 mg three times a day)
Trial: 1978500
Drug: Remoxipride (150-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (150-600 mg/day)
Trial: 1978500
Drug: Haloperidol (5-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5-45 mg/day)
Trial: 7017492
Drug: Broncaspin suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broncaspin suspension (3 tablespoonfuls a day)
Trial: 7017492
Drug: Recognised commercial
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recognised commercial preparation (3 tablespoonfuls a day)
Trial: 27015720
Drug: Dialectical Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical Behavior Therapy adapted for adolescents (DBT-A)
Trial: 31127612
Drug: DBT-A with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBT-A with more than 3 months follow-up treatment
Trial: 19844234
Drug: Lapatinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib monotherapy (1500 mg once daily)
Trial: 17537071
Drug: Conjoint family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjoint family therapy (CFT)
Trial: 17537071
Drug: Separated family
RxNorm normalized name: serrated swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separated family therapy (SFT)
Trial: 17142202
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg + HCTZ 12.5 mg
Trial: 17142202
Drug: Olmesartan 20
RxNorm normalized name: olmesartan 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 20 mg + HCTZ 12.5 mg
Trial: 6594713
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg naloxone
Trial: 29777663
Drug: Etonogestrel implant
RxNorm normalized name: Etonogestrel Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etonogestrel implant (ENG)
Trial: 25722221
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/day) plus Metformin (850 mg twice daily after meals)
Trial: 25722221
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/day) plus Placebo
Trial: 19014306
Drug: Outpatient treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient treatments for depression
Trial: 11284461
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium (500 mg/day, adjustable after 1-3 days)
Trial: 6851655
Drug: Amcinonide ointment
RxNorm normalized name: Amcinonide Ointment
DrugBank: Amcinonide (DB00288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcinonide ointment 0.1 percent twice a day
Trial: 6851655
Drug: Fluocinonide ointment
RxNorm normalized name: Fluocinonide Ointment
DrugBank: Fluocinonide (DB01047)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinonide ointment 0.05 percent three times a day
Trial: 28468770
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (400,000 IU oral vitamin D3, with an additional 200,000 IU if serum 25(OH)D was <100 nmol/L after 4 weeks)
Trial: 26042485
Drug: BF Spiromax
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BF Spiromax 160/4.5 μg
Trial: 26042485
Drug: BF Turbohaler
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BF Turbohaler 200/6 μg
Trial: 26042485
Drug: BF Spiromax
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BF Spiromax 320/9 μg
Trial: 26042485
Drug: BF Turbohaler
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BF Turbohaler 400/12 μg
Trial: 17407625
Drug: Bisacodyl (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisacodyl (5-10 mg daily)
Trial: 17407625
Drug: Sodium picosulphate
RxNorm normalized name: Sodium Picosulfate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium picosulphate (5-10 mg daily)
Trial: 14627358
Drug: Yogurt supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt supplement (227 grams of commercial yogurt for 8 days)
Trial: 14627358
Drug: No yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No yogurt supplement
Trial: 1527431
Drug: Cefixime (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (single oral 400-mg dose)
Trial: 1527431
Drug: Ceftriaxone (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (single intramuscular 250-mg dose)
Trial: 15763605
Drug: Oxycodone alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone alone
Trial: 30734043
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of pioglitazone (titrated to 45 mg daily)
Trial: 11437041
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg b.i.d.) with ursodeoxycholic acid (250 mg t.i.d.)
Trial: 10489084
Drug: Paradoxical intention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Paradoxical intention included in treatment program
Trial: 10489084
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment program without paradoxical intention
Trial: 21716064
Drug: Acamprosate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate treatment for 12 weeks
Trial: 22563952
Drug: Acamprosate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate treatment
Trial: 19734379
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions) plus self-care advice
Trial: 16409565
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine injection at lunch-time
Trial: 16409565
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine injection at dinner-time
Trial: 16409565
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine injection at bed-time
Trial: 12849652
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy with recurrent MI during index hospitalization
Trial: 8730415
Drug: High blood-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High blood-flow (400 ml/min)
Trial: 8730415
Drug: Low blood-flow
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low blood-flow (200 ml/min)
Trial: 6313024
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of suxamethonium during halothane-nitrous oxide anaesthesia
Trial: 6313024
Drug: Prolonged infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged infusion of suxamethonium during fentanyl-nitrous oxide anaesthesia
Trial: 6313024
Drug: Neostigmine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine administration after stopping suxamethonium infusion
Trial: 3914838
Drug: XRT +
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XRT + chemotherapy (concomitant 5-FU during XRT and maintenance 5-FU + MeCCNU)
Trial: 3914838
Drug: XRT +
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XRT + chemotherapy
Trial: 24787263
Drug: Parent‐Child Interaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent‐Child Interaction Therapy (PCIT)
Trial: 25187584
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg daily for fifty days)
Trial: 22854605
Drug: Immediate-release oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oral diacetylmorphine (DAM)
Trial: 16393744
Drug: Slow-release oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oral morphine
Trial: 19717246
Drug: Experimenter-administered cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimenter-administered cocaine (0, 12.5, 25 and 50mg/70 kg, i.v.)
Trial: 19717246
Drug: Cocaine self-administration
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine self-administration (0, 12.5 and 25mg/70 kg, i.v.)
Trial: 10643347
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose methylprednisolone (500 mg once daily for five days with a 10 days tapering period)
Trial: 20597561
Drug: Metoclopramide 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.2 mg/kg intravenously
Trial: 26997579
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg/kg intravenously
Trial: 24835497
Drug: Lidocaine/tetracaine patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/tetracaine patch
Trial: 16022759
Drug: Purified high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified high-dose anthocyanoside oligomer (100 mg tablet comprising 85% anthocyanoside oligomer), administered twice daily for 4 weeks.
Trial: 16022759
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered twice daily for 4 weeks.